What approval did Pfizer (NYSE:PFE) receive for Xianweiying (ecnoglutide)?

Pfizer received approval from Chinese regulators, the National Medical Products Administration (NMPA), for its GLP-1 receptor agonist, Xianweiying (ecnoglutide), for long-term weight management in overweight and obese adults. Xianweiying is the first "cAMP-biased" GLP-1 treatment approved globally for obesity, offering a unique mechanism designed to enhance weight loss while potentially reducing gastrointestinal side effects.

How does Xianweiying (ecnoglutide) work differently from other GLP-1 treatments?

Xianweiying (ecnoglutide) works through a "cAMP-biased" mechanism, which differentiates it from other GLP-1 treatments. This mechanism is designed to enhance weight loss while potentially reducing the gastrointestinal side effects commonly associated with other GLP-1 receptor agonists

What strategic deal did Pfizer (NYSE:PFE) make in relation to Xianweiying (ecnoglutide)?

In February 2026, Pfizer finalized a licensing deal with Sciwind Biosciences, in which Pfizer paid up to $495 million for exclusive commercialization rights for Xianweiying in mainland China. While Sciwind will continue to manufacture and develop the drug, Pfizer will leverage its extensive sales infrastructure in China to compete in the weight management market.

How does the Chinese market for obesity treatments compare to its competitors?

The Chinese market for obesity treatments is competitive, with major players like Novo Nordisk’s Wegovy and Innovent Biologics’ Xinermei. In 2025, Xinermei outperformed Wegovy on major Chinese e-commerce platforms, with $61 million in sales compared to Wegovy’s $38 million, highlighting the strong competition that Pfizer will face with Xianweiying.

What makes Xianweiying (ecnoglutide) a unique treatment for obesity?

Xianweiying (ecnoglutide) is unique because it is the first "cAMP-biased" GLP-1 treatment approved globally for obesity. This innovative mechanism is designed to improve weight loss outcomes while potentially reducing the gastrointestinal side effects commonly seen with other GLP-1 receptor agonists.

Pfizer secures China approval for GLP-1 weight-loss drug Xianweiying

Written by Liezl GambePublished Mar. 6 2026Last Updated Mar. 6 2026

Pfizer (NYSE:PFE) significantly expanded its metabolic footprint on Friday, announcing that Chinese regulators have approved its GLP-1 receptor agonist, Xianweiying (ecnoglutide), for long-term weight management in overweight and obese adults.

The approval by the National Medical Products Administration (NMPA) makes Xianweiying the first "cAMP-biased" GLP-1 treatment approved globally for obesity, a unique mechanism designed to enhance weight loss while potentially reducing gastrointestinal side effects.

The move follows a strategic licensing deal finalized in February 2026, in which Pfizer paid Sciwind Biosciences up to $495 million for exclusive commercialization rights in mainland China.

While Sciwind remains the manufacturer and developer, Pfizer will leverage its vast Chinese sales infrastructure to challenge incumbents.

The market is currently dominated by Novo Nordisk's Wegovy and Innovent Biologics' Xinermei, the latter of which outperformed Wegovy on major Chinese e-commerce platforms in 2025 with $61 million in sales compared to Wegovy's $38 million.